These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21413853)

  • 21. [Locally advanced pancreatic carcinoma. Radiochemotherapy prolongs survival].
    Wilkowski R; Heinemann V; Rau H
    MMW Fortschr Med; 2000 Oct; 142(42):31-2. PubMed ID: 11077823
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer.
    Ho AL; Sherman E
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):32-41. PubMed ID: 21326144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wilms' tumor, pancreatic islet cell carcinoma, and pheochromocytoma in a child.
    Sola JE; Gutierrez JC; Thompson WR; Alvarez OA; Casillas J; Rodriguez MM
    J Pediatr Surg; 2008 Mar; 43(3):E25-9. PubMed ID: 18358270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
    Sankhala K; Giles FJ
    Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth.
    Takayama Y; Kokuryo T; Yokoyama Y; Nagino M; Nimura Y; Senga T; Hamaguchi M
    Cancer Lett; 2008 Jun; 264(2):241-9. PubMed ID: 18346844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MTOR mutations in the crosshairs of targeted therapy.
    Rejto PA; Abraham RT
    Cancer Discov; 2014 May; 4(5):513-5. PubMed ID: 24795009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
    Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
    Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
    Mounier N; Vignot S; Spano JP
    Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of a preclinical model of pancreas cancer to identify potential candidates for rapalogue therapy.
    Takeuchi KK; Crawford HC
    Gut; 2014 Sep; 63(9):1379-80. PubMed ID: 24966285
    [No Abstract]   [Full Text] [Related]  

  • 31. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
    Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Haferkamp A; Blaheta RA
    Cancer Lett; 2011 Feb; 301(1):17-28. PubMed ID: 21122981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
    Subbiah V; Trent JC; Kurzrock R
    J Clin Oncol; 2010 Aug; 28(24):e415. PubMed ID: 20567010
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.
    Kokkinakis DM; Ahmed MM; Delgado R; Fruitwala MM; Mohiuddin M; Albores-Saavedra J
    Cancer Res; 1997 Dec; 57(23):5360-8. PubMed ID: 9393761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.
    Sibaud V; Dalenc F; Mourey L; Chevreau C
    Acta Derm Venereol; 2011 Sep; 91(5):584-5. PubMed ID: 21667012
    [No Abstract]   [Full Text] [Related]  

  • 35. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
    Scott EC; Maziarz RT; Spurgeon SE; Medvedova E; Gajewski J; Reasor-Heard S; Park B; Kratz A; Thomas GV; Loriaux M; Cascio M; Podolak J; Gordon M; Botelho J; Stadtmauer E; Amaravadi R; Vogl DT
    Haematologica; 2017 Jul; 102(7):e261-e265. PubMed ID: 28385778
    [No Abstract]   [Full Text] [Related]  

  • 36. Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.
    Lakkakula BVKS; Farran B; Lakkakula S; Peela S; Yarla NS; Bramhachari PV; Kamal MA; Saddala MS; Nagaraju GP
    Semin Cancer Biol; 2019 Jun; 56():149-167. PubMed ID: 30314681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Systemic chemotherapy for unresectable pancreatic cancer].
    Naruge D; Nagashima F; Furuse J
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():148-51. PubMed ID: 25857004
    [No Abstract]   [Full Text] [Related]  

  • 38. [Toxicity management for mTOR inhibitors].
    Mukohara T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():272-6. PubMed ID: 25831766
    [No Abstract]   [Full Text] [Related]  

  • 39. Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials.
    Naing A
    Expert Opin Investig Drugs; 2013 Jun; 22(6):679-85. PubMed ID: 23631743
    [No Abstract]   [Full Text] [Related]  

  • 40. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice.
    Bergers G; Hanahan D
    Cold Spring Harb Symp Quant Biol; 2002; 67():293-300. PubMed ID: 12858552
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.